Kidney cancer is considered to be one of the 10 most common cancers affecting men and women across the globe. While the risk of kidney cancer is higher in men than in women, there are numerous factors that determine the risk of cancer. The two main types of kidney cancer are renal cell carcinoma (RCC) and transitional cell carcinoma (TCC), and kidney cancer drugs are generally administered to patients of stage four, advanced RCC.
According to the American Cancer Society, in the year 2015, approximately 61,560 new cases of kidney cancer will be registered in the United States alone, of which 23,290 will be women and 38,270 will be men. Out of these, around 14,080 people will die from the disease in 2015, of which 5,010 will be women and 9,070 will be men.
Browse Market Research Report @ http://www.transparencymarketresearch.com/kidney-cancer-drugs-market.html
The U.S. National Cancer Institute states that kidney cancer is more common among American Indian, African American, and Alaska Native populations. This makes North America a rather large and lucrative market for kidney cancer drugs.
Votrient: Most promising commercially available kidney cancer drug
There are a number of kidney cancer drugs that are prescribed, used, and commercially available today. Some of the major brands are Votrient (Pazopanib), Inlyta (Axitinib), Proleukin (Aldesleukin), Afinitor (Everolimus), Sutent (Sunitinib), Nexavar (Sorafenib), Torisel (Temsirolimus), and Avastin (Bevacizumab).
Of these, Sutent (Sunitinib) dominated the kidney cancer drugs market in 2013, accounting for 30% of the revenue share. Often considered to be the first line of treatment for renal cell carcinoma (RCC), Sutent is one of the most studied kidney cancer drugs for multiple indications. However, owing to its relatively high price, this drug is expected to register a rather meager growth rate of 1.1% from 2012 to 2016 and 2.1% from 2016 to 2020.
Votrient (Pazopanib), on the other hand, is projected to be the most promising kidney cancer drug during the forecast period and will witness the strongest growth between 2012 and 2020. According to a report by Transparency Market Research (TMR), Votrient is estimated to grow at an outstanding CAGR of 41.7% from 2012 to 2016, and 8.9% from 2016 to 2020.
U.S. largest pharmaceutical market in the world
The global kidney cancer drugs market is divided into four key geographic regions: North America, Europe, Asia-Pacific, and Rest of the World. The growing prevalence of kidney cancer makes North America the leading market for kidney cancer drugs; revenue-wise, this region held more than 45% of the total share in 2013. Split into Canada and the United States, the North America market is driven by a growing patient pool, commercial availability of leading drugs for the treatment of kidney cancer, a strong healthcare insurance base, and impressive healthcare systems customized for the pharmaceutical sector. The U.S. accounted for 90% of the North America kidney cancer drugs market.
For more information on this report, fill the form @ http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=537
The APAC region has also proved to be a lucrative market for kidney cancer drugs owing to a rising geriatric population, growing prevalence of kidney cancer, and economic recovery and growth in countries such as China, Japan, Australia, and New Zealand. Registering a 6% growth rate, the Asia-Pacific market for kidney cancer drugs is anticipated to be the fastest growing regional segment during the forecast period.
Market to register healthy growth rate owing to intense competition
The recently-published TMR report has indicated that the market for kidney cancer drugs is characterized by strong competition among industry participants. With the global market being immensely consolidated, there are only a handful of established pharmaceutical companies who dominate the kidney cancer drugs market. Some of the principal players operating in the market are GlaxoSmithKline, plc, F. Hoffmann-La Roche, Ltd., Pfizer, Inc., Bayer AG, and Novartis AG. Among these, Pfizer was the largest maker of kidney cancer drugs in the world and held more than 40% of the total market share in 2013.
The report states that this concentration of power in the hands of a few contributes to the growth of the kidney cancer drugs market. In 2013, the global market was valued at US$2.6 billion and this is estimated to reach US$4.5 billion by 2020, expanding at a compound annual growth rate of 6.6% till 2020.
Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Transparency Market Research
90 State Street, Suite 700
Albany, NY 12207
USA – Canada Toll Free: 866-552-3453